Comorbidity-Adjusted Survival in Early Stage Lung Cancer Patients Treated with Hypofractionated Proton Therapy

Objective. To determine the influence of comorbidity on survival in early-stage lung cancer patients treated with proton radiotherapy, using the Charlson Comorbidity Index.Study Design and Setting. Fifty-four non-small-cell lung cancer patients, treated prospectively in a phase II clinical trial with hypofractionated proton therapy, were analyzed retrospectively to assess their burden of comorbid disease as expressed by Charlson Comorbidity Index. Using the Charlson Comorbidity Index method, a predicted survival curve based on comorbidity was formulated and compared to the observed mortality from causes other than lung cancer in the study population.Results. The study population had an average age score of 2.8 and an average Charlson Comorbidity Index of 4.7. Predicted survival was calculated to be 67% and 50% at 2 and 4 years, respectively. Actual comorbidity-specific survival at 2 and 4 years was 64% and 45%, respectively. The observed survival fell within the 95% confidence intervals of the predicted survival at all time points up to 5 years.Conclusion. Predicted mortality from concurrent disease, based on Charlson Comorbidity Index, correlated well with observed comorbidity-specific mortality. This helps substantiate the accuracy of the data coding in cause of death and strengthens previously reported disease-specific survival rates.

Download Full-text

Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients

10.1183/13993003.congress-2021.pa2293 ◽

2021 ◽

Author(s):

Jonathan Groves ◽

Ryan Yeo ◽

Yat Tsang ◽

Nihal Shah ◽

Thida Win

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Clinical Outcomes ◽

Early Stage ◽

Early Stage Lung Cancer ◽

Lung Cancer Patients ◽

Stereotactic Ablative Body Radiotherapy ◽

Stage Lung Cancer

Download Full-text

Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage

PLoS ONE ◽

10.1371/journal.pone.0252304 ◽

2021 ◽

Vol 16 (6) ◽

pp. e0252304

Author(s):

Dirk Stefani ◽

Balazs Hegedues ◽

Stephane Collaud ◽

Mohamed Zaatar ◽

Till Ploenes ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Early Stage ◽

Stage Iv ◽

Tumor Stage ◽

Plasma Dna ◽

Early Stage Lung Cancer ◽

Lung Cancer Patients ◽

Stage Iv Lung Cancer ◽

Stage Lung Cancer

Background Torque teno virus (TTV) is a ubiquitous non-pathogenic virus, which is suppressed in immunological healthy individuals but replicates in immune compromised patients. Thus, TTV load is a suitable biomarker for monitoring the immunosuppression also in lung transplant recipients. Since little is known about the changes of TTV load in lung cancer patients, we analyzed TTV plasma DNA levels in lung cancer patients and its perioperative changes after lung cancer surgery. Material and methods Patients with lung cancer and non-malignant nodules as control group were included prospectively. TTV DNA levels were measured by quantiative PCR using DNA isolated from patients plasma and correlated with routine circulating biomarkers and clinicopathological variables. Results 47 patients (early stage lung cancer n = 30, stage IV lung cancer n = 10, non-malignant nodules n = 7) were included. TTV DNA levels were not detected in seven patients (15%). There was no significant difference between the stage IV cases and the preoperative TTV plasma DNA levels in patients with early stage lung cancer or non-malignant nodules (p = 0.627). While gender, tumor stage and tumor histology showed no correlation with TTV load patients below 65 years of age had a significantly lower TTV load then older patients (p = 0.022). Regarding routine blood based biomarkers, LDH activity was significantly higher in patients with stage IV lung cancer (p = 0.043), however, TTV load showed no correlation with LDH activity, albumin, hemoglobin, CRP or WBC. Comparing the preoperative, postoperative and discharge day TTV load, no unequivocal pattern in the kinetics were. Conclusion Our study suggest that lung cancer has no stage dependent impact on TTV plasma DNA levels and confirms that elderly patients have a significantly higher TTV load. Furthermore, we found no uniform perioperative changes during early stage lung cancer resection on plasma TTV DNA levels.

Download Full-text

Comparison of Wedge Resection Versus Wedge Resection Plus Cesium-131 Brachytherapy Versus Stereotactic Body Radiation Therapy in Management of Early Stage Lung Cancer Patients That Are Not Candidates for a Standard Lobectomy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.06.525 ◽

2013 ◽

Vol 87 (2) ◽

pp. S203-S204 ◽

Cited By ~ 1

Author(s):

B. Parashar ◽

S. Arora ◽

P. Christos ◽

J. Port ◽

A. Wernicke ◽

...

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Cancer Patients ◽

Stereotactic Body Radiation Therapy ◽

Early Stage ◽

Wedge Resection ◽

Early Stage Lung Cancer ◽

Lung Cancer Patients ◽

Stereotactic Body Radiation ◽

Stage Lung Cancer

Download Full-text

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-stage Lung Cancer Diagnosis

10.21203/rs.3.rs-97860/v1 ◽

2020 ◽

Author(s):

Lingling Wan ◽

Yutong He ◽

Qingyi Liu ◽

Di Liang ◽

Yongdong Guo ◽

...

Keyword(s):

Lung Cancer ◽

Early Diagnosis ◽

Cancer Patients ◽

Early Stage ◽

Untargeted Metabolomics ◽

Early Stage Lung Cancer ◽

Lung Cancer Patients ◽

Diagnosis Of Lung Cancer ◽

Metabolomics Analysis ◽

Stage Lung Cancer

Abstract Background: Lung cancer is a malignant tumor that has the highest morbidity and mortality rate among all cancers. Early diagnosis of lung cancer is a key factor in reducing mortality and improving prognosis. Methods: In this study, we performed CTC next-generation sequencing (NGS) in early-stage lung cancer patients to identify lung cancer-related gene mutations. Meanwhile, a serum liquid chromatography-tandem mass spectrometry (LC-MS) untargeted metabolomics analysis was performed in the CTC-positive patients, and the early diagnostic value of these assays in lung cancer was analyzed. Results: 62.5% (30/48) of lung cancer patients had ≥ 1 CTC. By CTC NGS, we found that > 50% of patients had 4 commonly mutated genes, namely, NOTCH1, IGF2, EGFR, and PTCH1. 47.37% (9/19) patients had ARIDH1 mutations. Additionally, 30 CTC-positive patients and 30 healthy volunteers were subjected to LC-MS untargeted metabolomics analysis. We found 100 different metabolites, and 10 different metabolites were identified through analysis, which may have potential clinical application value in the diagnosis of CTC-positive early-stage lung cancer (AUC > 0.9). Conclusions: Our results indicate that NGS of CTC and metabolomics may provide new tumor markers for the early diagnosis of lung cancer. This possibility requires more in-depth large-sample research for verification.

Download Full-text